Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testofen for Post COVID-19 Symptoms
NCT05795816Phase 3Completed
- Sponsor
- RDC Clinical
- Start
- Oct 2023
- Primary completion
- Jan 2025
- Modality
- Dietary Supplement
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-COVID-19 condition (PCC) comparing Testofen Arm with Placebo Arm (2 arms). Primary endpoint: Change in Energy and Fatigue at 12 weeks. Started Oct 2023; status: completed.
02
Drugs
fenugreek extract
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT05795816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795816.